Diabetes Care, Vol 22, Issue 1 99-111, Copyright © 1999 by American Diabetes Association

ARTICLES

Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort

OBJECTIVE: The Diabetes Control and Complications Trial (DCCT) demonstrated the powerful impact of glycemic control on the early manifestations of microvascular complications. Contemporary prospective data on the evolution of macrovascular and late microvascular complications of type 1 diabetes are limited. The Epidemiology of Diabetes Interventions and Complications (EDIC) study is a multicenter, longitudinal, observational study designed to use the well-characterized DCCT cohort of > 1,400 patients to determine the long-term effects of prior separation of glycemic levels on micro- and macrovascular outcomes. RESEARCH DESIGN AND METHODS: Using a standardized annual history and physical examination, 28 EDIC clinical centers that were DCCT clinics will follow the EDIC cohort for 10 years. Annual evaluation also includes resting electrocardiogram. Doppler ultrasound measurements of ankle/arm blood pressure, and screening for nephropathy. At regular intervals, a timed 4-h urine is collected, lipid profiles are obtained, and stereoscopic fundus photographs are taken. In addition, dual B-mode Doppler ultrasound scans of the common and internal carotid arteries will be performed at years 1 and 6 and at study end. RESULTS: Written informed consent was obtained from 96% of the DCCT subjects. The participants, compared with nonparticipants, tended to have better glycemic control at the completion of the DCCT and were more likely to have their diabetes care provided by DCCT personnel. The EDIC baseline measurement stratified by sex delineates multiple cardiovascular disease risk factor differences such as age (older in men), waist-to-hip ratio (higher in men). HDL cholesterol (lower in men), hypertension (more prevalent in men), and maximum intimal-medial thickness of common and internal carotid arteries (thicker in men). Of the original conventional treatment group, 69% have changed to continuous subcutaneous insulin infusion or multiple daily injections. Although the mean HbA1c difference between the intensive and conventional treatment groups narrowed at EDIC years 1 and 2, HbA1c remained significantly lower in the intensive group. Of all expected clinic visits, 95% were completed, and the quality of EDIC data is very similar to that observed in the DCCT. CONCLUSIONS: Although obvious problems exist in extended follow-up studies of completed clinical trials, these are balanced by the value of continued systematic observation of the DCCT cohort. In contrast to other epidemiologic studies, EDIC will provide 1) definitive data on type 1 as distinct from type 2 diabetes; 2) reliance on prospective rather than on cross-sectional analysis; 3) long-term follow-up in a large population; 4) consistent use of objective, reliable measures of outcomes and glycemia; and 5) observation of patients from before the onset of complications.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Diabetes Control and Complications Trial/Epidemiol Prolonged Effect of Intensive Therapy on the Risk of Retinopathy Complications in Patients With Type 1 Diabetes Mellitus: 10 Years After the Diabetes Control and Complications Trial Arch Ophthalmol, December 1, 2008; 126(12): 1707 - 1715. [Abstract] [Full Text] [PDF]

				G. Musen, A. M. Jacobson, C. M. Ryan, P. A. Cleary, B. H. Waberski, K. Weinger, W. Dahms, M. Bayless, N. Silvers, J. Harth, et al. Impact of Diabetes and Its Treatment on Cognitive Function Among Adolescents Who Participated in the Diabetes Control and Complications Trial Diabetes Care, October 1, 2008; 31(10): 1933 - 1938. [Abstract] [Full Text] [PDF]

				E S Kilpatrick Haemoglobin A1c in the diagnosis and monitoring of diabetes mellitus J. Clin. Pathol., September 1, 2008; 61(9): 977 - 982. [Abstract] [Full Text] [PDF]

				H. H Moffet, N. Adler, D. Schillinger, A. T Ahmed, B. Laraia, J. V Selby, R. Neugebauer, J. Y Liu, M. M Parker, M. Warton, et al. Cohort Profile: The Diabetes Study of Northern California (DISTANCE)--objectives and design of a survey follow-up study of social health disparities in a managed care population Int. J. Epidemiol., March 7, 2008; (2008) dyn040v1. [Full Text] [PDF]

				R. E. Carter, D. T. Lackland, P. A. Cleary, E. Yim, M. F. Lopes-Virella, G. E. Gilbert, T. J. Orchard, and for the Diabetes Control and Complications Trial/E Intensive Treatment of Diabetes Is Associated With a Reduced Rate of Peripheral Arterial Calcification in The Diabetes Control and Complications Trial Diabetes Care, October 1, 2007; 30(10): 2646 - 2648. [Full Text] [PDF]

				J. W. Albers, W. H. Herman, R. Pop-Busui, C. L. Martin, P. Cleary, B. Waberski, and for the Diabetes Control and Complications Trial ( Subclinical Neuropathy Among Diabetes Control and Complications Trial Participants Without Diagnosable Neuropathy at Trial Completion: Possible predictors of incident neuropathy? Diabetes Care, October 1, 2007; 30(10): 2613 - 2618. [Abstract] [Full Text] [PDF]

				A. D. Paterson, B. N. Rutledge, P. A. Cleary, J. M. Lachin, R. S. Crow, and for the Diabetes Control and Complications Trial/E The Effect of Intensive Diabetes Treatment on Resting Heart Rate in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Diabetes Care, August 1, 2007; 30(8): 2107 - 2112. [Abstract] [Full Text] [PDF]

				S. D. Sibley, I. H. de Boer, M. W. Steffes, J. D. Brunzell, and the Diabetes Control and Complications Trial/Epide Intra-Abdominal Fat and Elevated Urine Albumin Excretion in Men With Type 1 Diabetes Diabetes Care, July 1, 2007; 30(7): 1898 - 1900. [Full Text] [PDF]

				The Diabetes Control and Complications Trial/Epide Long-Term Effect of Diabetes and Its Treatment on Cognitive Function N. Engl. J. Med., May 3, 2007; 356(18): 1842 - 1852. [Abstract] [Full Text] [PDF]

				J. R. Gavin III An Uncompromising Approach to Achieving Glycemic Goals The Diabetes Educator, March 1, 2007; 33(Supplement_3): 52S - 59S. [Full Text] [PDF]

				W. Darby The Experiences of School Nurses Caring for Students Receiving Continuous Subcutaneous Insulin Infusion Therapy The Journal of School Nursing, December 1, 2006; 22(6): 336 - 344. [Abstract] [Full Text] [PDF]

				P. A. Cleary, T. J. Orchard, S. Genuth, N. D. Wong, R. Detrano, J.-Y. C. Backlund, B. Zinman, A. Jacobson, W. Sun, J. M. Lachin, et al. The Effect of Intensive Glycemic Treatment on Coronary Artery Calcification in Type 1 Diabetic Participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Diabetes, December 1, 2006; 55(12): 3556 - 3565. [Abstract] [Full Text] [PDF]

				D. J. Ramsey, H. Ripps, and H. Qian An Electrophysiological Study of Retinal Function in the Diabetic Female Rat Invest. Ophthalmol. Vis. Sci., November 1, 2006; 47(11): 5116 - 5124. [Abstract] [Full Text] [PDF]

				S. S. Soedamah-Muthu, J. H. Fuller, H. E. Mulnier, V. S. Raleigh, R. A. Lawrenson, and H. M. Colhoun High Risk of Cardiovascular Disease in Patients With Type 1 Diabetes in the U.K.: A cohort study using the General Practice Research Database Diabetes Care, April 1, 2006; 29(4): 798 - 804. [Abstract] [Full Text] [PDF]

				C. L. Martin, J. Albers, W. H. Herman, P. Cleary, B. Waberski, D. A. Greene, M. J. Stevens, and E. L. Feldman Neuropathy Among the Diabetes Control and Complications Trial Cohort 8 Years After Trial Completion Diabetes Care, February 1, 2006; 29(2): 340 - 344. [Abstract] [Full Text] [PDF]

				J. R. Sedor Frontiers in Diabetic Nephropathy: Can We Predict Who Will Get Sick? J. Am. Soc. Nephrol., February 1, 2006; 17(2): 336 - 338. [Full Text] [PDF]

				The Diabetes Control and Complications Trial/Epide Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes N. Engl. J. Med., December 22, 2005; 353(25): 2643 - 2653. [Abstract] [Full Text] [PDF]

				W. T. Cefalu Glycemic Control and Cardiovascular Disease -- Should We Reassess Clinical Goals? N. Engl. J. Med., December 22, 2005; 353(25): 2707 - 2709. [Full Text] [PDF]

				R. Bottino and M. Trucco Multifaceted Therapeutic Approaches for a Multigenic Disease Diabetes, December 1, 2005; 54(suppl_2): S79 - S86. [Abstract] [Full Text] [PDF]

				S. Genuth, W. Sun, P. Cleary, D. R. Sell, W. Dahms, J. Malone, W. Sivitz, V. M. Monnier, and for the DCCT Skin Collagen Ancillary Study Group Glycation and Carboxymethyllysine Levels in Skin Collagen Predict the Risk of Future 10-Year Progression of Diabetic Retinopathy and Nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications Participants With Type 1 Diabetes Diabetes, November 1, 2005; 54(11): 3103 - 3111. [Abstract] [Full Text] [PDF]

				M. Steffes, P. Cleary, D. Goldstein, R. Little, H.-M. Wiedmeyer, C. Rohlfing, J. England, J. Bucksa, M. Nowicki, and the DCCT/EDIC Research Group Hemoglobin A1c Measurements over Nearly Two Decades: Sustaining Comparable Values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study Clin. Chem., April 1, 2005; 51(4): 753 - 758. [Abstract] [Full Text] [PDF]

				S.A. Saunders, M. Wallymahmed, and I.A. MacFarlane Glycaemic control in a type 1 diabetes clinic for younger adults QJM, September 1, 2004; 97(9): 575 - 580. [Abstract] [Full Text] [PDF]

				T. J. Lyons, A. J. Jenkins, D. Zheng, D. T. Lackland, D. McGee, W. T. Garvey, and R. L. Klein Diabetic Retinopathy and Serum Lipoprotein Subclasses in the DCCT/EDIC Cohort Invest. Ophthalmol. Vis. Sci., March 1, 2004; 45(3): 910 - 918. [Abstract] [Full Text] [PDF]

				D. A. Butler and M. T. Lawlor It Takes a Village: Helping Families Live With Diabetes Diabetes Spectr, January 1, 2004; 17(1): 26 - 31. [Abstract] [Full Text] [PDF]

				Writing Team for the Diabetes Control and Complica Sustained Effect of Intensive Treatment of Type 1 Diabetes Mellitus on Development and Progression of Diabetic Nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study JAMA, October 22, 2003; 290(16): 2159 - 2167. [Abstract] [Full Text] [PDF]

				J. Q. Purnell, R. K. Dev, M. W. Steffes, P. A. Cleary, J. P. Palmer, I. B. Hirsch, J. E. Hokanson, and J. D. Brunzell Relationship of Family History of Type 2 Diabetes, Hypoglycemia, and Autoantibodies to Weight Gain and Lipids With Intensive and Conventional Therapy in the Diabetes Control and Complications Trial Diabetes, October 1, 2003; 52(10): 2623 - 2629. [Abstract] [Full Text] [PDF]

				S. D. Sibley, J. P. Palmer, I. B. Hirsch, and J. D. Brunzell Visceral Obesity, Hepatic Lipase Activity, and Dyslipidemia in Type 1 Diabetes J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3379 - 3384. [Abstract] [Full Text] [PDF]

				E Hathout, J Lakey, and J Shapiro Islet transplant: an option for childhood diabetes? Arch. Dis. Child., July 1, 2003; 88(7): 591 - 594. [Abstract] [Full Text] [PDF]

				The Diabetes Control and Complications Trial/Epide Intensive Diabetes Therapy and Carotid Intima-Media Thickness in Type 1 Diabetes Mellitus N. Engl. J. Med., June 5, 2003; 348(23): 2294 - 2303. [Abstract] [Full Text] [PDF]

				R. L. Klein, S. J. Hunter, A. J. Jenkins, D. Zheng, A. J. Semler, J. Clore, W. T. Garvey, and The DCCT/EDIC Study Group Fibrinogen Is a Marker for Nephropathy and Peripheral Vascular Disease in Type 1 Diabetes: Studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort Diabetes Care, May 1, 2003; 26(5): 1439 - 1448. [Abstract] [Full Text] [PDF]

				A. A. Jaffa, R. Durazo-Arvizu, D. Zheng, D. T. Lackland, S. Srikanth, W. T. Garvey, and A. H. Schmaier Plasma Prekallikrein: A Risk Marker for Hypertension and Nephropathy in Type 1 Diabetes Diabetes, May 1, 2003; 52(5): 1215 - 1221. [Abstract] [Full Text] [PDF]

				G. E. Umpierrez, K. A. Latif, M. B. Murphy, H. C. Lambeth, F. Stentz, A. Bush, and A. E. Kitabchi Thyroid Dysfunction in Patients With Type 1 Diabetes: A longitudinal study Diabetes Care, April 1, 2003; 26(4): 1181 - 1185. [Abstract] [Full Text] [PDF]

				A. J. Jenkins, T. J. Lyons, D. Zheng, J. D. Otvos, D. T. Lackland, D. McGee, W. T. Garvey, R. L. Klein, and The DCCT/EDIC Research Group Serum Lipoproteins in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Cohort: Associations with gender and glycemia Diabetes Care, March 1, 2003; 26(3): 810 - 818. [Abstract] [Full Text] [PDF]

				R. R. Little, C. L. Rohlfing, H.-M. Wiedmeyer, G. L. Myers, D. B. Sacks, and D. E. Goldstein The National Glycohemoglobin Standardization Program: A Five-Year Progress Report Clin. Chem., November 1, 2001; 47(11): 1985 - 1992. [Abstract] [Full Text] [PDF]

				Retinopathy in Patients With Type 1 Diabetes 4 Years After Intensive Therapy Arch Ophthalmol, July 1, 2000; 118(7): 984 - 985. [Full Text] [PDF]

				The Diabetes Control and Complications Trial/Epide Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years after a Trial of Intensive Therapy N. Engl. J. Med., February 10, 2000; 342(6): 381 - 389. [Abstract] [Full Text] [PDF]